PYRAMID-ANALYTICS
31.8.2022 16:29:38 CEST | Business Wire | Press release
Pyramid Analytics (Pyramid), a pioneering decision intelligence platform provider, today announced the launch of a UK Public Sector Practice. The new division will bring the transformational power of augmented analytics to public departments, agencies and public bodies across the United Kingdom. Decision Intelligence enabled by AI and machine learning can modernize the delivery of critical public services, including healthcare, utilities, and transportation in Europe’s largest public sector market. There are 23 ministerial departments, 20 non-ministerial departments, 417 agencies and other public bodies, and 14 public corporations in the UK1.
Key Points:
- The Guardian reported that UK government spending on technology R&D is estimated to reach £14.9 billion for 2021 and 2022, and the government aims to increase this to £22 billion by 2026–27.
- The UK Public Sector practice will be led by Alastair Roriston, an experienced leader of successful programmes to connect technology with the needs of government agencies.
- Pyramid has a long track record of enabling technology innovation in the public sector. Government customers include the United States Department of Veterans Affairs, Israel Aerospace Industries, Israel Defense Forces, Ministry of Defence of the Republic of Slovenia, and Statistics Finland.
- The Pyramid Decision Intelligence Platform, training and services will be provided directly and through partnerships.
- Decision Intelligence will help frontline public sector workers to make faster and more informed decisions, elevating the level of service for the general public.
A New Future for the UK Public Sector
The COVID-19 pandemic accelerated digital transformation across all sectors of the economy and society, and government needs to keep pace. Spearheaded with a clear mandate from Cabinet Office, the UK government is leading the way in reimagining how data can be used to improve the operations of the public sector and the standard of service they offer to ordinary people every day.
NHS England unveiled plans in April to develop a federated data platform (FDP), with an estimated procurement value of £240 million. According to the notice, the FDP will be “an ecosystem of technologies and services” and “an essential enabler to transformational improvements across the NHS”. It will be built around five major use cases: population health and person insight, care co-ordination, elective recovery, vaccines and immunisation, and the supply chain.
Pyramid Experience with Massive Public Healthcare Systems
The Pyramid Decision Intelligence Platform is currently used by the United States Department of Veteran Affairs (VA), a Cabinet-level executive branch department of the federal government charged with providing life-long healthcare services to eligible military veterans at the 170 medical centers and outpatient clinics located throughout the country. The VA provides comprehensive healthcare services to 9 million veterans.
The Pyramid Decision Intelligence Platform is used by clinical, medical and administrative staff to identify patterns and execution gaps across the system, ensuring US military veterans receive more personalised and enhanced care. So far, a programme run by just three people has trained 40,000 staff in the use of the platform, with plans to eventually equip 60,000 to start using Decision Intelligence to improve the services they offer to US military veterans and their families.
Decision Intelligence is the Next Big Data Analytics Innovation
The next major innovation in analytics is Artificial Intelligence (AI). Applying AI across Data Prep, Business Analytics, and Data Science is what separates Decision Intelligence from traditional business intelligence tools such as Microsoft Power BI, Qlik, and Tableau. AI lowers the skills barrier by automating the highly technical work needed to prepare and analyze data and create and share reports and dashboards.
The Pyramid Decision Intelligence Platform delivers data-driven insights for anyone to make faster, more intelligent decisions. The Pyramid Platform provides instant access to any data, enables automated governed self-service for any person, and serves any analytics need, from the simple to the sophisticated. By uniquely combining Data Prep, Business Analytics, and Data Science with AI guidance in a single environment, the Pyramid Platform reduces cost and complexity while accelerating growth and innovation. This enables a strategic, organization-wide approach to Business Intelligence and Analytics.
Quotes
Tom Warren, Regional Managing Director, UKI, Pyramid Analytics:
“The Pyramid family are excited to announce this next chapter of our story. We look forward to enabling the digital transformation of UK public sector organisations, helping to deliver better, faster and more efficient services to those who need them the most. We hope to use Decision Intelligence to turn data analytics in the public sector from the complex to the simple with decision intelligence.
“I am excited to be working with the highly experienced and forward-thinking Alastair Roriston to advance Pyramid’s expansion into the UK public sector. He joins an already successful and high-performing team, who have been instrumental to Pyramid’s expansion in the UKI. With Alastair’s expertise, the sky is the limit.”
Alastair Roriston, Director of Sales UK Public Sector, Pyramid Analytics:
“I am thrilled to have joined this innovative and ground-breaking company and even keener to assist in its expansion into the UK public sector. Throughout my career, I have seen the huge positive impact when the essential work of the public sector is married to the cutting-edge possibilities of technology – the opportunity for change is nearly limitless.
“I truly believe that Pyramid’s decision intelligence platform will revolutionise how government and public sector organisations deliver their digital and online services. Far too often, the wheels of public services are held up by siloed systems and antiquated approaches to data. A doctor should not have to wait precious minutes or hours for reports and patient data to arrive. Why should they not have that information and advice on next steps available in moments? Decision intelligence can eliminate these inefficiencies, making every frontline public sector worker a citizen data scientist with a world of dynamic, augmented analytics at their fingertips.”
About Pyramid Analytics
Pyramid is what’s next in analytics. Our unified decision intelligence platform delivers insights for everyone to make faster, more informed decisions. It provides direct access to any data, enables governed self-service for any person, and serves any analytics need in a no-code environment. Decision Intelligence Platform uniquely combines Data Prep, Business Analytics, and Data Science in a single environment with AI guidance, reducing cost and complexity while accelerating growth and innovation. The Pyramid Platform enables a strategic, organization-wide approach to Business Intelligence and Analytics, from the simple to the sophisticated. Schedule a demo.
Pyramid Analytics is incorporated in Amsterdam and has regional headquarters in global innovation and business centers, including London, New York City, and Tel Aviv. Our team lives worldwide because geography should not be a barrier to talent and opportunity. Learn more at Pyramid Analytics.
1 GOV.UK
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220831005204/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
